Is a Triplet or Quadruplet Regimen More Effective in Managing Newly Diagnosed Multiple Myeloma?

Posted: Tuesday, March 5, 2024

Prashant Kapoor, MD, of the Mayo Clinic, Minnesota, discusses the phase III PERSEUS study, a late-breaking abstract at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. The study showed that adding subcutaneous daratumumab to VRd induction (bortezomib, lenalidomide, and dexamethasone) and to consolidation therapy and lenalidomide maintenance therapy improved progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma.

---